FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia

(2010) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vitro Enzymatic Characterization of Near Full Length EGFR in Activated and Inhibited States

(2009) Chen Qiu et al.   BIOCHEMISTRY

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

(2009) J. Zhou et al.   BLOOD

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

(2009) Y. Shiotsu et al.   BLOOD

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

(2008) K. W. Pratz et al.   BLOOD

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

(2008) Z. Zeng et al.   BLOOD

Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse

(2008) Gemma Molyneux et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens

(2008) Keith Pratz et al.   LEUKEMIA & LYMPHOMA